Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Beijing Avistone Pharmaceuticals Biotechnology.

    Client Virtual Booth

    BEIJING AVISTONE PHARMACEUTICALS BIOTECHNOLOGY

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Beijing Avistone Pharmaceuticals Biotechnology
    China Flag
    Country
    Country
    China
    Address
    Address
    Lize Middle 2nd Road, Chaoyang District, Beijing
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://en.avistonebio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/avistone-biotechnology-co-inc/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China

    Details:

    APL-101 (vebreltinib) is a highly specific cMet inhibitor which is indicated for the treatment of sGBM/IDH mutant glioblastoma with the ZM fusion gene.


    Lead Product(s): Vebreltinib

    Therapeutic Area: Oncology Product Name: PLB1001

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 25, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Avistone Biotechnology Announces Closing of Series B Financing

    Details:

    The net proceeds will be used to support clinical research and development of the Avistone pipeline, including PLB1001 (vebreltinib), a small-molecule inhibitor that targets MET tyrosine kinase activity.


    Lead Product(s): Vebreltinib

    Therapeutic Area: Oncology Product Name: PLB1001

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: SDIC CS Capital

    Deal Size: $140.0 million Upfront Cash: Undisclosed

    Deal Type: Series B Financing January 04, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    bora-pharmaceuticals-2024-07-01

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search